NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound
March 04, 2025 15:13 ET
|
NanoNewron
Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 04, 2025 14:06 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025 09:01 ET
|
Alumis Inc.
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities
March 04, 2025 08:30 ET
|
Irazu Oncology
Dr. Mayukh Das, joined Irazú as CMO, bringing extensive oncology drug development experience from leadership roles at global pharmaceutical companies.
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025 09:08 ET
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Pharming Group to participate in March investor conference
February 28, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Zhittya Genesis Medicine Announces: Landmark fMRI Study Reveals 21.2% Boost in Brain Blood Flow in Parkinson’s Patient Following Six Months of Intranasal FGF-1 Therapy
February 27, 2025 11:00 ET
|
Zhittya Genesis Medicine Inc
Groundbreaking fMRI study that showed a 21.2% increase in brain blood flow in a Parkinson’s patient after six months of intranasal FGF1 therapy.
Precision Neuroscience Expands Clinical Research in Brain–Computer Interface Through Collaboration with Beth Israel Deaconess Medical Center
February 27, 2025 09:00 ET
|
Precision Neuroscience
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation, a pioneering brain–computer interface (BCI) company, today announced a clinical research project with Beth Israel...
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
February 27, 2025 08:00 ET
|
ALX Oncology
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
February 27, 2025 08:00 ET
|
Genesis Research Group
Partnership Underscores Commitment to Advancing Health Economics and Outcomes Research Excellence HOBOKEN, NJ -- February 27 -- Genesis Research Group, a pioneer of tech-enabled real-world evidence...